-
-
-
-
-
-
-
Baird Reiterates Outperform Rating on Editas Medicine (EDIT) following earnings
-
-
-
-
-
-
-
Editas Medicine reports 90% LDL cholesterol reduction in animal studies
-
-
-
-
-
-
-
Editas Medicine (EDIT) Misses Q2 EPS by 23c
-
-
-
-
-
-
-
Editas Medicine (EDIT) Announces CFO Change
-
-
-
-
-
-
-
Editas Medicine (EDIT) PT Lowered to $4 at RBC Capital on Lead Program Termination
-
-
-
-
-
-
-
BofA Securities Double Upgrades Editas Medicine (EDIT) to Buy
-
-
-
-
-
-
-
Editas Medicine (EDIT) Reports In-Line Q3 EPS
-
456,419 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

